ARISING HEALTHALIVE. AWAKE. AWARE.Follow The Arising ↗

Arising Health · Podcast

The Arising Signal.

The Arising’s reporting on longevity, medicine, and the business of health, in audio.

A sunlit observatory overlooking the sea

Latest episode

· 10:34

The difference between knowing and knowing what to do

Six stories from the November 18 edition ask what a finding actually changes: a blood test that can guide treatment for some advanced breast cancers, a blood marker that helps estimate cognitive risk, a trial of eating windows and liver fat, supervised exercise after 60, plaque-measuring software, and a Medicare pilot that ties payment to outcomes. This episode uses an AI-generated version of John Griffin’s voice.

Earlier episodes

  1. · 16:26

    What a number can tell you, and what it can’t

    John Griffin revisits what the November 16 reporting can and can’t tell us: postwar sugar rationing and biological-age estimates, shingles vaccination and dementia research, measuring perimenopause symptoms, protein and health, and a once-weekly HIV treatment trial. This episode uses an AI-generated version of John Griffin’s voice.

  2. · 27:21

    Hormone therapy and heart risk

    Sarah and Michael open with a study of hormone therapy in midlife. They also discuss mitochondrial replacement in fertility clinics, a liver fibrosis trial, and investment in senior housing.

  3. · 18:52

    What do slow waves during REM sleep tell us?

    Sleep researchers are finding unexpected patterns in REM sleep as people age. Also in this edition: a heart valve designed for growing children, biological age estimates, and changes in Medicare Advantage.

  4. · 16:05

    Remission in type 2 diabetes

    The hosts discuss the RESET trial in younger adults with type 2 diabetes, a small trial in liver fibrosis, and changes to estrogen patch labeling.

  5. · 10:34

    A pill for sleep apnea?

    An investigational pill for sleep apnea leads this edition. Sarah and Michael also cover a gene-editing trial, blood pressure medication, and what happens after people stop taking tirzepatide.

  6. · 11:00

    An early glaucoma trial

    What can researchers learn from the first three patients in a reprogramming trial? The hosts also discuss a melanoma vaccine, bone density during weight loss, and an Alzheimer’s trial.

THE ARISING NEWSLETTER

Science moves forward.
Come with it.

Research, clear explanations, and a little room for wonder.
Read and follow The Arising on Substack.

Find The Arising on Substack ↗